Effect of Apabetalone on Cardiovascular Events in Diabetes, CKD, and Recent Acute Coronary Syndrome
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Effect of Apabetalone on Cardiovascular Events in Diabetes, CKD, and Recent Acute Coronary Syndrome
Authors
Keywords
-
Journal
Clinical Journal of the American Society of Nephrology
Volume 16, Issue 5, Pages 705-716
Publisher
American Society of Nephrology (ASN)
Online
2021-04-28
DOI
10.2215/cjn.16751020
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effect of Apabetalone Added to Standard Therapy on Major Adverse Cardiovascular Events in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes
- (2020) Kausik K. Ray et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of selective BET protein inhibitor apabetalone on cardiovascular outcomes in patients with acute coronary syndrome and diabetes: Rationale, design, and baseline characteristics of the BETonMACE trial
- (2019) Kausik K. Ray et al. AMERICAN HEART JOURNAL
- Apabetalone lowers serum alkaline phosphatase and improves cardiovascular risk in patients with cardiovascular disease
- (2019) Mathias Haarhaus et al. ATHEROSCLEROSIS
- Apabetalone Mediated Epigenetic Modulation is Associated with Favorable Kidney Function and Alkaline Phosphatase Profile in Patients with Chronic Kidney Disease
- (2018) Ewelina Kulikowski et al. KIDNEY & BLOOD PRESSURE RESEARCH
- Targeting epigenetic DNA and histone modifications to treat kidney disease
- (2018) Miguel Fontecha-Barriuso et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Apabetalone downregulates factors and pathways associated with vascular calcification
- (2018) Dean Gilham et al. ATHEROSCLEROSIS
- Alkaline phosphatase: a novel treatment target for cardiovascular disease in CKD
- (2017) Mathias Haarhaus et al. Nature Reviews Nephrology
- Liraglutide and Renal Outcomes in Type 2 Diabetes
- (2017) Johannes F.E. Mann et al. NEW ENGLAND JOURNAL OF MEDICINE
- BRD4 is a histone acetyltransferase that evicts nucleosomes from chromatin
- (2016) Ballachanda N Devaiah et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- BRD4 is a histone acetyltransferase that evicts nucleosomes from chromatin
- (2016) Ballachanda N Devaiah et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Serum Alkaline Phosphatase Negatively Affects Endothelium-Dependent Vasodilation in Naïve Hypertensive PatientsNovelty and Significance
- (2015) Francesco Perticone et al. HYPERTENSION
- Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial
- (2015) Dick de Zeeuw et al. Lancet Diabetes & Endocrinology
- Impact of Achieved Blood Pressures on Mortality Risk and End-Stage Renal Disease Among a Large, Diverse Hypertension Population
- (2014) John J. Sim et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- NF-κB Directs Dynamic Super Enhancer Formation in Inflammation and Atherogenesis
- (2014) Jonathan D. Brown et al. MOLECULAR CELL
- BRD4 assists elongation of both coding and enhancer RNAs by interacting with acetylated histones
- (2014) Tomohiko Kanno et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Outcomes Associated With Microalbuminuria
- (2013) Csaba P. Kovesdy et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Relation Between Alkaline Phosphatase, Serum Phosphate, and All-Cause or Cardiovascular Mortality
- (2009) Marcello Tonelli et al. CIRCULATION
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now